# An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)

> **NCT01012622** · PHASE4 · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 142 (actual)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity

## Interventions

- **DRUG:** Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride

## Key facts

- **NCT ID:** NCT01012622
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2014-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01012622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01012622, "An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01012622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*